These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 9702818)

  • 1. [Screening in prostate carcinoma].
    Wirth MP; Spiegel T; Froschermaier SE; Manseck A
    Z Arztl Fortbild Qualitatssich; 1998 Jun; 92(5):304-9. PubMed ID: 9702818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Advancements in PSA-based screening for prostate cancer].
    Ito K
    Rinsho Byori; 2004 Jul; 52(7):611-7. PubMed ID: 15344561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial.
    Andriole GL; Levin DL; Crawford ED; Gelmann EP; Pinsky PF; Chia D; Kramer BS; Reding D; Church TR; Grubb RL; Izmirlian G; Ragard LR; Clapp JD; Prorok PC; Gohagan JK;
    J Natl Cancer Inst; 2005 Mar; 97(6):433-8. PubMed ID: 15770007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate carcinoma detection and increased prostate-specific antigen levels after 4 years in Dutch and Japanese males who had no evidence of disease at initial screening.
    Ito K; Raaijmakers R; Roobol M; Wildhagen M; Yamanaka H; Schröder FH
    Cancer; 2005 Jan; 103(2):242-50. PubMed ID: 15578715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate cancer screening within a prostate specific antigen range of 3 to 3.9 ng./ml.: a comparison of digital rectal examination and free prostate specific antigen as supplemental screening tests.
    Mäkinen T; Tammela TL; Hakama M; Stenman UH; Rannikko S; Aro J; Juusela H; Määttänen L; Auvinen A
    J Urol; 2001 Oct; 166(4):1339-42. PubMed ID: 11547069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early detection of prostate cancer. Decreasing the mortality rate.
    Oesterling JE
    Minn Med; 1996 Apr; 79(4):46-9. PubMed ID: 8637492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate specific antigen testing and digital rectal examination before and during a randomized trial of screening for prostate cancer: European randomized study of screening for prostate cancer, Rotterdam.
    Beemsterboer PM; de Koning HJ; Kranse R; Trienekens PH; van der Maas PJ; Schröder FH
    J Urol; 2000 Oct; 164(4):1216-20. PubMed ID: 10992369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Early detection of cancer of the prostate. Pros and cons].
    Hoesl CE; Altwein JE
    MMW Fortschr Med; 2005 Apr; 147(14):32, 34-6. PubMed ID: 15887681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Mass screening for prostate cancer in Nagano].
    Ishizuka O; Satoh T; Kobayashi S; Nishizawa O
    Hinyokika Kiyo; 2001 Nov; 47(11):769-72. PubMed ID: 11771167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate cancer and prostate-specific antigen (PSA) screening in Austria.
    Vutuc C; Schernhammer ES; Haidinger G; Waldhör T
    Wien Klin Wochenschr; 2005 Jul; 117(13-14):457-61. PubMed ID: 16091872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate cancer risk assessment program: a 10-year update of cancer detection.
    Giri VN; Beebe-Dimmer J; Buyyounouski M; Konski A; Feigenberg SJ; Uzzo RG; Hanks G; Godwin AK; Chen DY; Gordon R; Cescon T; Raysor S; Watkins-Bruner D
    J Urol; 2007 Nov; 178(5):1920-4; discussion 1924. PubMed ID: 17868726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PSA as a screening test for prostate cancer.
    Crawford ED; DeAntoni EP
    Urol Clin North Am; 1993 Nov; 20(4):637-46. PubMed ID: 7505971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Results and participation factors to the European Randomized study of Screening for Prostate Cancer (ERSPC) with Prostate Specific Antigen: French departments of Tarn and Hérault].
    Jegu J; Tretarre B; Grosclaude P; Rebillard X; Bataille V; Malavaud B; Iborra F; Salama G; Rischmann P; Villers A
    Prog Urol; 2009 Jul; 19(7):487-98. PubMed ID: 19559380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Model of screening for prostatic cancer among patients with prostate specific antigen concentration of 4-10 ng/ml in blood].
    Karazanashvili GG; Managadze LG
    Urologiia; 2000; (6):37-41. PubMed ID: 11186321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prostate cancer screening using prostate-specific antigen (PSA) determinations in plasma. National Academy of Medicine].
    Bourel M; Ardaillou R;
    Bull Acad Natl Med; 2003; 187(5):985-95. PubMed ID: 14979060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lead time of prostate cancer detected in population based screening for prostate cancer in Japan.
    Ito K; Yamamoto T; Miyakubo M; Takechi H; Ohi M; Shibata Y; Suzuki K
    J Urol; 2007 Oct; 178(4 Pt 1):1258-63; discussion 1263-4. PubMed ID: 17698107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prostate tumor and its diagnosis].
    Yamanaka H
    Rinsho Byori; 2001 Jul; 49(7):633-7. PubMed ID: 11519121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interval cancers in prostate cancer screening: comparing 2- and 4-year screening intervals in the European Randomized Study of Screening for Prostate Cancer, Gothenburg and Rotterdam.
    Roobol MJ; Grenabo A; Schröder FH; Hugosson J
    J Natl Cancer Inst; 2007 Sep; 99(17):1296-303. PubMed ID: 17728218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma.
    Hugosson J; Aus G; Lilja H; Lodding P; Pihl CG
    Cancer; 2004 Apr; 100(7):1397-405. PubMed ID: 15042673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml. range.
    Haese A; Dworschack RT; Partin AW
    J Urol; 2002 Aug; 168(2):504-8. PubMed ID: 12131298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.